Article Details
Retrieved on: 2025-03-28 20:07:19
Tags for this article:
Click the tags to see associated articles and topics
Summary
Vertex Pharmaceuticals, a biotechnology company in Boston, is advancing research in treating Type 1 diabetes, an autoimmune disease. They report setbacks with VX-264 but progress with zimislecel, addressing insulin production and hypoglycemia. Tags relate to their T1D focus.
Article found on: investors.vrtx.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here